Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CB307 |
Synonyms | |
Therapy Description |
CB307 is a bispecific Humabody that acts as an agonist of TNFRSF9 (CD137) and targets prostate-specific membrane antigen (PSMA) and human serum albumin (HSA), potentially inducing T-cell activation against PSMA-expressing tumor cells and inhibiting tumor growth (PMID: 38593226). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CB307 | CB-307|CB 307 | CB307 is a bispecific Humabody that acts as an agonist of TNFRSF9 (CD137) and targets prostate-specific membrane antigen (PSMA) and human serum albumin (HSA), potentially inducing T-cell activation against PSMA-expressing tumor cells and inhibiting tumor growth (PMID: 38593226). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04839991 | Phase I | CB307 | Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) | Recruiting | USA | NLD | GBR | ESP | 0 |